Scholarlink

Background <p>Hemodialysis (HD) is a method of kidney replacement therapy designed to remove uremic toxins from the body. Beta-2 microglobulin (beta-2 MG) is a middle molecule not yet effectively removed by conventional low-flux dialysis membranes and may contribute to long-term complications in chronic HD patients. While well-studied in adults, data in pediatric populations are limited. This study evaluated beta-2 MG levels before and after HD in children and assessed associations with dialysis prescription parameters and cardiovascular comorbidities.</p> Methods <p>A cross-sectional study was conducted from June to July 2024 at the Kiara Children’s Dialysis Unit, Rumah Sakit Umum Pusat Nasional (RSUPN) Cipto Mangunkusumo, Indonesia. Pre- and post-HD beta-2 MG levels were measured. Dialysis prescriptions, laboratory values, and cardiovascular parameters were recorded and analyzed for correlations with beta-2 MG levels and reduction ratios.</p> Results <p>The study involved 38 subjects, of whom 22 (57.9%) were male, with an average age of 13.2 ± 2.9&#xa0;years. Most patients received HD twice weekly. Pre-HD beta-2 MG levels were elevated in all patients. Synthetic-based high-flux dialyzers were significantly associated with greater beta-2 MG reduction ratios compared to cellulose-based low-flux membranes (<i>r </i>= 0.716; <i>p</i> = 0.000). No significant correlations were found between beta-2 MG levels and other HD parameters, laboratory markers, or cardiovascular outcomes.</p> Conclusions <p>Synthetic-based high-flux dialyzers were associated with improved beta-2 MG clearance in pediatric HD patients, though pre-HD levels were comparable across membrane types. Further longitudinal studies are warranted to determine the clinical significance of beta-2 MG reduction and guide dialysis optimization in children.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Correlation of serum beta-2 microglobulin with hemodialysis prescription and comorbid factors in children undergoing chronic hemodialysis

  • 期刊论文

  • 发表日期：

    2025年11月17日

查看全文
  • Budyarini Prima Sari,
  • Sudung O. Pardede,
  • Pustika Amalia Wahidiyat,
  • Aman Pulungan,
  • Eka Laksmi Hidayati,
  • Piprim Basarah Yanuarso

摘要

Background

Hemodialysis (HD) is a method of kidney replacement therapy designed to remove uremic toxins from the body. Beta-2 microglobulin (beta-2 MG) is a middle molecule not yet effectively removed by conventional low-flux dialysis membranes and may contribute to long-term complications in chronic HD patients. While well-studied in adults, data in pediatric populations are limited. This study evaluated beta-2 MG levels before and after HD in children and assessed associations with dialysis prescription parameters and cardiovascular comorbidities.

Methods

A cross-sectional study was conducted from June to July 2024 at the Kiara Children’s Dialysis Unit, Rumah Sakit Umum Pusat Nasional (RSUPN) Cipto Mangunkusumo, Indonesia. Pre- and post-HD beta-2 MG levels were measured. Dialysis prescriptions, laboratory values, and cardiovascular parameters were recorded and analyzed for correlations with beta-2 MG levels and reduction ratios.

Results

The study involved 38 subjects, of whom 22 (57.9%) were male, with an average age of 13.2 ± 2.9 years. Most patients received HD twice weekly. Pre-HD beta-2 MG levels were elevated in all patients. Synthetic-based high-flux dialyzers were significantly associated with greater beta-2 MG reduction ratios compared to cellulose-based low-flux membranes (r = 0.716; p = 0.000). No significant correlations were found between beta-2 MG levels and other HD parameters, laboratory markers, or cardiovascular outcomes.

Conclusions

Synthetic-based high-flux dialyzers were associated with improved beta-2 MG clearance in pediatric HD patients, though pre-HD levels were comparable across membrane types. Further longitudinal studies are warranted to determine the clinical significance of beta-2 MG reduction and guide dialysis optimization in children.